Hennion & Walsh Asset Management Inc. Has $1.40 Million Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Hennion & Walsh Asset Management Inc. raised its position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 34.7% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 117,595 shares of the company’s stock after acquiring an additional 30,283 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Olema Pharmaceuticals were worth $1,404,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of OLMA. Cubist Systematic Strategies LLC bought a new position in shares of Olema Pharmaceuticals in the 2nd quarter worth $145,000. SG Americas Securities LLC bought a new position in shares of Olema Pharmaceuticals in the third quarter valued at $156,000. Entropy Technologies LP acquired a new position in shares of Olema Pharmaceuticals during the first quarter valued at about $161,000. Ensign Peak Advisors Inc increased its position in shares of Olema Pharmaceuticals by 6.1% during the second quarter. Ensign Peak Advisors Inc now owns 14,849 shares of the company’s stock worth $161,000 after acquiring an additional 850 shares in the last quarter. Finally, EntryPoint Capital LLC increased its position in shares of Olema Pharmaceuticals by 949.9% during the first quarter. EntryPoint Capital LLC now owns 14,530 shares of the company’s stock worth $164,000 after acquiring an additional 13,146 shares in the last quarter. Institutional investors own 91.78% of the company’s stock.

Insider Activity at Olema Pharmaceuticals

In other Olema Pharmaceuticals news, major shareholder Biocapital Advisors L. Paradigm sold 2,400,000 shares of Olema Pharmaceuticals stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $14.91, for a total value of $35,784,000.00. Following the sale, the insider now owns 783,118 shares of the company’s stock, valued at approximately $11,676,289.38. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Olema Pharmaceuticals news, major shareholder Biocapital Advisors L. Paradigm sold 2,400,000 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $14.91, for a total value of $35,784,000.00. Following the completion of the sale, the insider now directly owns 783,118 shares of the company’s stock, valued at $11,676,289.38. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Cyrus Harmon sold 4,066 shares of the company’s stock in a transaction on Monday, July 29th. The shares were sold at an average price of $15.58, for a total value of $63,348.28. Following the transaction, the director now directly owns 752,217 shares in the company, valued at $11,719,540.86. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 19.40% of the stock is owned by company insiders.

Olema Pharmaceuticals Stock Down 1.5 %

Shares of NASDAQ OLMA opened at $11.55 on Friday. The company has a market capitalization of $646.04 million, a PE ratio of -5.72 and a beta of 2.02. The stock’s 50 day moving average price is $12.05 and its 200-day moving average price is $11.84. Olema Pharmaceuticals, Inc. has a twelve month low of $8.51 and a twelve month high of $17.79.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.54) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.54). As a group, research analysts expect that Olema Pharmaceuticals, Inc. will post -1.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on OLMA. JPMorgan Chase & Co. dropped their price target on shares of Olema Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Oppenheimer reaffirmed an “outperform” rating and set a $30.00 target price on shares of Olema Pharmaceuticals in a research report on Wednesday, August 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Olema Pharmaceuticals in a research report on Thursday. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $27.00.

Olema Pharmaceuticals Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.